Therapeutic Response

dMMR status confers therapeutic sensitivity to Dostarlimab in patients with Endometrial Carcinoma.

Statements

Source and description
Jemperli (dostarlimab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
Jemperli (dostarlimab) [product information]. EMA. The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.